Literature DB >> 19427582

Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions.

Pitchai Balakumar1, Mandeep Kumar Arora, Subrahmanya S Ganti, Jayarami Reddy, Manjeet Singh.   

Abstract

Chronic diabetes mellitus is associated with various complications such as retinopathy, neuropathy, nephropathy, cardiomyopathy, vasculopathy, dermatopathy and encephalopathy. Nephropathy is one of the major complications of diabetes mellitus, and the morbidity and mortality due to diabetic nephropathy is constantly progressing in industrialized nations. No satisfactory therapeutic option is currently available to treat patients with nephropathy except for fewer agents like angiotensin converting enzyme inhibitors, angiotensin AT(1) receptor blockers and few antioxidants, which have been shown to improve the function of diabetic kidney to some extent. Thus, tremendous efforts are being made to explore promising therapeutic interventions to treat diabetic nephropathy. This review discussed various presently employed and recently developed pharmacological interventions to treat diabetic nephropathy and to improve the function of diabetic kidney. In addition, the recently identified potential target sites involved in the pathogenesis of diabetic nephropathy have been delineated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427582     DOI: 10.1016/j.phrs.2009.02.002

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  19 in total

Review 1.  Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis.

Authors:  Ying Li; Yan Ge; Fu You Liu; You Ming Peng; Lin Sun; Jun Li; Qiong Chen; Yan Sun; Kun Ye
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

Review 2.  Mast cells and metabolic syndrome.

Authors:  Jie Zhang; Guo-Ping Shi
Journal:  Biochim Biophys Acta       Date:  2010-12-23

Review 3.  New molecular insights in diabetic nephropathy.

Authors:  Ionel Alexandru Checheriţă; Gina Manda; Mihai Eugen Hinescu; Ileana Peride; Andrei Niculae; Ştefana Bîlha; Angelica Grămăticu; Luminiţa Voroneanu; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

4.  Diabetes-induced renal injury in rats is attenuated by suramin.

Authors:  Midhun C Korrapati; Brooke E Shaner; Benjamin A Neely; Joseph L Alge; John M Arthur; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2012-06-26       Impact factor: 4.030

Review 5.  A novel improved therapy strategy for diabetic nephropathy: targeting AGEs.

Authors:  Xuemei Zhou; Bochu Wang; Liancai Zhu; Shilei Hao
Journal:  Organogenesis       Date:  2012-01-01       Impact factor: 2.500

6.  Pathogenic role of mast cells in the development of diabetic nephropathy: a study of patients at different stages of the disease.

Authors:  J M Zheng; G H Yao; Z Cheng; R Wang; Z H Liu
Journal:  Diabetologia       Date:  2011-12-01       Impact factor: 10.122

Review 7.  Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.

Authors:  Aina He; Guo-Ping Shi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 8.  Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy?

Authors:  Pitchai Balakumar; Jayarami Reddy; Manjeet Singh
Journal:  Mol Cell Biochem       Date:  2009-05-05       Impact factor: 3.396

9.  MicroRNA-214 antagonism protects against renal fibrosis.

Authors:  Laura Denby; Vasudev Ramdas; Ruifang Lu; Bryan R Conway; Jennifer S Grant; Brent Dickinson; Arin B Aurora; John D McClure; David Kipgen; Christian Delles; Eva van Rooij; Andrew H Baker
Journal:  J Am Soc Nephrol       Date:  2013-10-24       Impact factor: 10.121

10.  Acute and subchronic in-vivo effects of Ferula hermonis L. and Sambucus nigra L. and their potential active isolates in a diabetic mouse model of neuropathic pain.

Authors:  K Raafat; A El-Lakany
Journal:  BMC Complement Altern Med       Date:  2015-07-30       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.